Shares of Fortress Biotech, Inc. (NASDAQ:FBIO – Get Rating) received a consensus “moderate buy” recommendation from the seven ratings companies that currently cover the company, MarketBeat Ratings reports. One investment analyst gave the stock a hold rating and five gave the company a buy rating. The 12-month average target price among brokers who have hedged the stock over the past year is $12.00.
A number of research analysts have weighed in on the company recently. StockNews.com upgraded Fortress Biotech from a “sell” rating to a “hold” rating in a Thursday, May 19 research note. Roth Capital reissued a “buy” rating on Fortress Biotech shares in a research note on Tuesday, March 29. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $6.00 price target on Fortress Biotech shares in a research note on Friday, May 13.
Shares of Fortress Biotech opened at $0.85 on Thursday. The company has a market capitalization of $90.76 million, a price-earnings ratio of -0.98 and a beta of 2.17. The company has a debt ratio of 0.46, a current ratio of 3.31 and a quick ratio of 3.15. Fortress Biotech has a 52 week low of $0.77 and a 52 week high of $3.81. The stock has a 50-day simple moving average of $0.90 and a 200-day simple moving average of $1.47.
Fortress Biotech (NASDAQ:FBIO – Get Rating) last released its quarterly earnings data on Thursday, May 12. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, beating analyst consensus estimates of ($0.28) by $0.10. Fortress Biotech had a negative return on equity of 32.56% and a negative net margin of 88.31%. The company posted revenue of $23.93 million for the quarter, versus a consensus estimate of $20.06 million. During the same period last year, the company achieved EPS of ($0.11). As a group, equity research analysts expect Fortress Biotech to post -0.77 earnings per share for the current year.
Hedge funds and other institutional investors have recently changed their stakes in the company. Advisor Group Holdings Inc. increased its position in Fortress Biotech by 113.0% in Q1. Advisor Group Holdings Inc. now owns 20,020 shares of the biopharmaceutical company worth $27,000 after purchasing an additional 10,620 shares during the period. Envestnet Asset Management Inc. bought a new position in Fortress Biotech in Q1 worth around $33,000. ProShare Advisors LLC bought a new position in Fortress Biotech in Q4 worth approximately $41,000. Mirabella Financial Services LLP bought a new position in Fortress Biotech in Q1 worth approximately $42,000. Finally, Lazard Asset Management LLC bought a new position in Fortress Biotech in Q4 worth around $56,000. 30.92% of the shares are currently held by institutional investors.
About Fortress Biotech (Get a rating)
Fortress Biotech, Inc., a biopharmaceutical company, develops and markets pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of moderate to severe non-nodular acne vulgaris; Targadox for severe acne; Exelderm cream for symptoms of ringworm and jock itch; Ceracade for dry skin; Luxamend for dressing and treating wounds; and Accutane capsules for severe recalcitrant nodular acne.
Get news and reviews for Fortress Biotech Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Fortress Biotech and related companies with MarketBeat.com’s free daily email newsletter.